Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review

Detalhes bibliográficos
Autor(a) principal: de Souza, Jackeline Martins Eberhardt
Data de Publicação: 2021
Outros Autores: Lazzaretti, Camilla
Tipo de documento: Artigo
Idioma: por
Título da fonte: Saúde e Desenvolvimento Humano
Texto Completo: https://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487
Resumo: Depression is one of the major mental illnesses of the century, being one of the major causes of morbidity and disability. Antidepressants (AD) currently on the market seem to increase concentrations of monoamines in the brain (dopamine, noradrenaline and serotonin). However, ADs have unwanted side effects, and this has motivated research on drugs with differentiated mechanisms of action. It is known that in the depressive state the circadian cycle is altered, resulting in damages in the sleep phases and wake, and consequently in the concentrations of melatonin (MEL). MEL is an important hormone related to the synchronization of the circadian cycle, and is closely linked with depressive states and insomnia. With these data, the objective of this work was to investigate through a literature review, the relationship of the melatoninergic system with depression and treatment with agomelatine. As a method, studies related to the descriptors: “depression and melatonin” were searched in the search platforms:”Scielo, PubMed and BVS (lilacs)”. The results obtained show that, of the studies evaluated, they mostly refers to agomelatine, an AD drug analogous to melatonin. AGOM has promising results in clinical and preclinical research to treat problems related to insomnia and depression, representing an innovation in drugs for this therapeutic purpose. It was concluded that the melatoninergic system is closely linked to depressive states and agomelatine presents as a promising drug for the treatment of depression associated with sleep and virile cycle disorders.
id UNILASALLE-6_479543f128872881fe0ead81b238711c
oai_identifier_str oai:ojs.revistas.unilasalle.edu.br:article/5487
network_acronym_str UNILASALLE-6
network_name_str Saúde e Desenvolvimento Humano
repository_id_str
spelling Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature reviewDepressão e as implicações do sistema de Melatonina e tratamento com Agomelatina: uma revisão de literaturaDepression; Melatonin; AgomelatineNeurociênciasDepressão; Melatonina; AgomelatinaDepression is one of the major mental illnesses of the century, being one of the major causes of morbidity and disability. Antidepressants (AD) currently on the market seem to increase concentrations of monoamines in the brain (dopamine, noradrenaline and serotonin). However, ADs have unwanted side effects, and this has motivated research on drugs with differentiated mechanisms of action. It is known that in the depressive state the circadian cycle is altered, resulting in damages in the sleep phases and wake, and consequently in the concentrations of melatonin (MEL). MEL is an important hormone related to the synchronization of the circadian cycle, and is closely linked with depressive states and insomnia. With these data, the objective of this work was to investigate through a literature review, the relationship of the melatoninergic system with depression and treatment with agomelatine. As a method, studies related to the descriptors: “depression and melatonin” were searched in the search platforms:”Scielo, PubMed and BVS (lilacs)”. The results obtained show that, of the studies evaluated, they mostly refers to agomelatine, an AD drug analogous to melatonin. AGOM has promising results in clinical and preclinical research to treat problems related to insomnia and depression, representing an innovation in drugs for this therapeutic purpose. It was concluded that the melatoninergic system is closely linked to depressive states and agomelatine presents as a promising drug for the treatment of depression associated with sleep and virile cycle disorders.A depressão é uma das principais doenças mentais do século, sendo uma das maiores causas de morbidade e invalidez. Os antidepressivos (AD) atualmente no mercado buscam aumentar as concentrações de monoaminas no encéfalo (dopamina, noradrenalina e serotonina). Todavia, os AD possuem efeitos colaterais indesejados, e isto tem motivado a pesquisa sobre medicamentos com mecanismos de ação diferenciados. Sabe- se, que no estado depressivo o ciclo circadiano é alterado, resultando em prejuízos nos estados de sono e vigília e consequentemente nas concentrações de melatonina (MEL). A MEL é um importante hormônio relacionado com a sincronização do ciclo circadiano, e está intimamente ligada com estados depressivos e insônia. Com estes dados, o objetivo do trabalho foi investigar através de uma revisão de literatura, a relação do sistema melatoninérgico com a depressão e seu tratamento com agomelatina (AGOM). Como método, foram pesquisados estudos relacionados aos descritores: “depressão e melatonina”, nas plataformas de busca: ”Scielo, PubMed e BVS (lilacs)”. Os resultados obtidos mostram, que dos estudos avaliados, em sua maioria cita a agomelatina, um fármaco AD análogo à melatonina. A AGOM possui resultados promissores em pesquisas clínicas e pré-clínicas para tratar problemas relacionados a insônia e a depressão, representando uma inovação nos fármacos com esta finalidade terapêutica. Concluiu-se, que o sistema melatoninérgico está intimamente ligado a estados depressivos e a agomelatina se apresenta como um fármaco promissor para o tratamento da depressão associada com alterações do ciclo sono e vigília.Universidade LaSalle - Unilasalle Canoasde Souza, Jackeline Martins EberhardtLazzaretti, Camilla2021-02-26info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/548710.18316/sdh.v9i1.5487Saúde e Desenvolvimento Humano; v. 9, n. 1 (2021)Saúde e Desenvolvimento Humano; v. 9, n. 1 (2021)2317-8582reponame:Saúde e Desenvolvimento Humanoinstname:Universidade La Salle (UNILASALLE)instacron:UNILASALLEporhttps://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487/pdfDireitos autorais 2021 Saúde e Desenvolvimento Humanoinfo:eu-repo/semantics/openAccess2022-03-23T16:14:39Zoai:ojs.revistas.unilasalle.edu.br:article/5487Revistahttp://www.revistas.unilasalle.edu.br/index.php/saude_desenvolvimentohttps://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/oaisdh@unilasalle.edu.br2317-85822317-8582opendoar:2022-03-23T16:14:39Saúde e Desenvolvimento Humano - Universidade La Salle (UNILASALLE)false
dc.title.none.fl_str_mv Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
Depressão e as implicações do sistema de Melatonina e tratamento com Agomelatina: uma revisão de literatura
title Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
spellingShingle Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
de Souza, Jackeline Martins Eberhardt
Depression; Melatonin; Agomelatine
Neurociências
Depressão; Melatonina; Agomelatina
title_short Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
title_full Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
title_fullStr Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
title_full_unstemmed Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
title_sort Depression and the implications of the Melatonin system and treatment with Agomelatine: a literature review
author de Souza, Jackeline Martins Eberhardt
author_facet de Souza, Jackeline Martins Eberhardt
Lazzaretti, Camilla
author_role author
author2 Lazzaretti, Camilla
author2_role author
dc.contributor.none.fl_str_mv

dc.contributor.author.fl_str_mv de Souza, Jackeline Martins Eberhardt
Lazzaretti, Camilla
dc.subject.none.fl_str_mv
dc.subject.por.fl_str_mv Depression; Melatonin; Agomelatine
Neurociências
Depressão; Melatonina; Agomelatina
topic Depression; Melatonin; Agomelatine
Neurociências
Depressão; Melatonina; Agomelatina
description Depression is one of the major mental illnesses of the century, being one of the major causes of morbidity and disability. Antidepressants (AD) currently on the market seem to increase concentrations of monoamines in the brain (dopamine, noradrenaline and serotonin). However, ADs have unwanted side effects, and this has motivated research on drugs with differentiated mechanisms of action. It is known that in the depressive state the circadian cycle is altered, resulting in damages in the sleep phases and wake, and consequently in the concentrations of melatonin (MEL). MEL is an important hormone related to the synchronization of the circadian cycle, and is closely linked with depressive states and insomnia. With these data, the objective of this work was to investigate through a literature review, the relationship of the melatoninergic system with depression and treatment with agomelatine. As a method, studies related to the descriptors: “depression and melatonin” were searched in the search platforms:”Scielo, PubMed and BVS (lilacs)”. The results obtained show that, of the studies evaluated, they mostly refers to agomelatine, an AD drug analogous to melatonin. AGOM has promising results in clinical and preclinical research to treat problems related to insomnia and depression, representing an innovation in drugs for this therapeutic purpose. It was concluded that the melatoninergic system is closely linked to depressive states and agomelatine presents as a promising drug for the treatment of depression associated with sleep and virile cycle disorders.
publishDate 2021
dc.date.none.fl_str_mv 2021-02-26
dc.type.none.fl_str_mv
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487
10.18316/sdh.v9i1.5487
url https://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487
identifier_str_mv 10.18316/sdh.v9i1.5487
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revistas.unilasalle.edu.br/index.php/saude_desenvolvimento/article/view/5487/pdf
dc.rights.driver.fl_str_mv Direitos autorais 2021 Saúde e Desenvolvimento Humano
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Direitos autorais 2021 Saúde e Desenvolvimento Humano
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade LaSalle - Unilasalle Canoas
publisher.none.fl_str_mv Universidade LaSalle - Unilasalle Canoas
dc.source.none.fl_str_mv Saúde e Desenvolvimento Humano; v. 9, n. 1 (2021)
Saúde e Desenvolvimento Humano; v. 9, n. 1 (2021)
2317-8582
reponame:Saúde e Desenvolvimento Humano
instname:Universidade La Salle (UNILASALLE)
instacron:UNILASALLE
instname_str Universidade La Salle (UNILASALLE)
instacron_str UNILASALLE
institution UNILASALLE
reponame_str Saúde e Desenvolvimento Humano
collection Saúde e Desenvolvimento Humano
repository.name.fl_str_mv Saúde e Desenvolvimento Humano - Universidade La Salle (UNILASALLE)
repository.mail.fl_str_mv sdh@unilasalle.edu.br
_version_ 1749120543934644224